TABLE 2

Description of Various Case Reports With SGLT2 Inhibitor–Associated DKA

StudyKarakaya et al.Yeo et al. (24)Chou et al. (25)Sloan et al. (26)Chakinala et al. (27)
Characteristics(23)
72-year-old woman with type 2 diabetes23-year-old woman with type 2 diabetes61-year-old woman with type 2 diabetes63-year-old man with type 2 diabetes61-year-old man with type 2 diabetes
SGLT2 inhibitorDapagliflozinDapagliflozinDapagliflozinCanagliflozinDapagliflozin
Trigger(s)SurgeryAcute pancreatitis, acute insulinopenia, colitisDecreased oral intakeDecreased oral intake, myocardial infarction, diverticulitisDecreased oral intake, insulinopenia
Glucose, mg/dL136148180239409
Bicarbonate, mEq/L9.21.87814
Anion gap, mEq/L20.723.820Elevated (value not reported)22
pH6.97.0296.9867.157.34
BHOB, mmol/L (reference range
<0.5)
81.685.2Not reported
Urine ketones/serum ketonesPositive2+/2+PositivePositivePositive
Creatinine, mg/dL1.260.810.80.89Not reported
Lactate, mmol/L (reference 0.5–1.8)1.71.61Not reported0.8
TreatmentIV insulin + hydrationContinuous renal replacement therapyIV insulin + hydrationIV insulin + antibiotics + antiplateletIV insulin + hydration